Objective: To study the factors affecting the time to onset of ocular graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
A llogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established therapeutic modality for neoplastic and non-neoplastic hematological disorders. The number of patients receiving this therapy has increased following improvements in human leukocyte antigen (HLA) matching and advances in pre-transplant and post-transplant regimens.
1,2 Newer therapeutic approaches, assisted by better supportive care, have helped enhance survival during the posttransplant period. 3 This has, however, led to emergence of complications due to prolonged patient survival. Graft-versushost disease (GVHD) is a common cause of morbidity and mortality after HSCT.
The incidence of ocular GVHD is 40% to 60% in patients receiving allo-HSCT. 4, 5 The incidence of chronic ocular GVHD occurring within 3 years of transplantation in adults and children is widely variable and ranges from 30% to 85%. 6 Historically, ocular GVHD has been considered to be a manifestation of extensive systemic GVHD that includes signs and symptoms of dry eyes. 7 Symptoms of chronic ocular GVHD are irritation, burning, pain, redness, grittiness, foreign body sensation, excessive tearing, sensitivity to light, and blurred vision; these symptoms impair quality of life and activities of daily living. 8 Clinical findings of the ocular surface in GVHD may include acute conjunctival inflammation, conjunctival hyperemia and chemosis, pseudomembranous and cicatricial conjunctivitis, severe corneal epitheliopathy, filaments, painful erosions, corneal ulceration, perforation, and scarring. 9 There are high concordance rates between acute and chronic systemic GVHD, and acute GVHD has been shown to be a strong predictor of chronic GVHD. One study reported that patients with acute GVHD had a greater risk of chronic GVHD. 10 As a result, risk factors for acute GVHD may by extension also apply to chronic GVHD. Studies have demonstrated a strong association between dry eye and both acute and chronic systemic GVHD. 11, 12 Risk factors for subsequent development of ocular GVHD include skin and mouth involvement, peripheral blood stem cell transplantation, male donor to female recipient, and a history of acute GVHD. 7, 8 One review showed that the limited effect of treatments for ocular GVHD can sometimes be a consequence of patients presenting at an advanced stage of the disease, when permanent damage to the tissues is already present. 13 The objective of this study was to evaluate the time elapsed from allo-HSCT to the onset of ocular GVHD and to identify its associated factors, which would allow for monitoring patients at risk leading to earlier diagnosis and management.
MATERIALS AND METHODS
This was a retrospective study from records of postallo-HSCT patients presenting with ocular GVHD at the Cornea Service, Massachusetts Eye and Ear Infirmary (MEEI), between May 2007 and September 2011. Approval was obtained from the MEEI Institutional Review Board, and the study was carried out following the tenets of the Declaration of Helsinki. Records of 200 post-allo-HSCT patients, flagged as oncology protocol patients and presenting for evaluation of dry eye and ocular surface inflammation, were reviewed. Details about allo-HSCT and diagnosis of nonocular systemic GVHD, reported by the oncology team, were obtained from electronic medical records. All patients included in the final analysis underwent transplantation in hospitals affiliated with the Harvard Cancer Center (Dana-Farber Cancer Institute and Massachusetts General Hospital, Boston, MA). Chronic ocular GVHD was diagnosed in patients who presented with all of the following: (1) history of allo-HSCT; (2) exclusively post-HSCT self-reported onset of dry eye symptoms including irritation, burning, dryness or foreign body sensation (Ocular Surface Disease Index; OSDI score .33) that required treatment with frequent topical lubricants or antiinflammatory eye drops; and (3) signs of ocular surface disease that included any 2 of the following: decreased Schirmer test (#5 mm), presence of corneal fluorescein staining (modified Oxford scale), and decreased tear breakup time (#10 seconds) confirmed by a cornea specialist. Most patients presented with a previous diagnosis of systemic GVHD, and were diagnosed with definite ocular GVHD, whereas patients without a previous diagnosis of systemic GVHD were diagnosed as probable ocular GVHD. For the purpose of our analyses, patients with diagnoses of definite and probable ocular GVHD were combined.
The onset of ocular GVHD was defined by the date of the patient's first report of symptoms entered in the medical records, provided that the presence of ocular signs was later confirmed at the MEEI Cornea Clinic. Time (days) elapsed between the transplant and onset of ocular GVHD was analyzed for all patients as well as in different subgroups defined by donor-recipient matching characteristics. The subgroups analyzed were defined by the donor status as follows: genotypically identical siblings or other related 6/6 HLA-matched donor (matched-related donor), matchedunrelated donor, and 5/6 HLA-matched donor (mismatchedunrelated donor). Time elapsed between the onset of systemic GVHD and diagnosis of ocular GVHD was also analyzed. Additionally, we calculated the time elapsed from HSCT to onset of ocular GVHD in different groups defined by donorrecipient gender mismatch (male donor to female recipient, female donor to male recipient) status, conditioning and prophylactic regimens, recipient age, and involvement of systemic organs. We excluded patients with incomplete records regarding details of their HSCT. Patients with other ocular conditions such as, but not limited to, herpetic eye disease, scleritis, episcleritis, and glaucoma (using multiple anti-glaucoma medications), which may confound the diagnosis of ocular GVHD were also excluded.
Statistical Analysis
Data are presented as mean or median 6 SD and range for continuous variables and percentages for categorical variables. Because of the non-normal distribution of some of the data, presenting the median reflects a more accurate figure of the actual data. We used the Mann-Whitney U test for 2-sample analysis and the Kruskal-Wallis test, including post hoc tests for multiple comparisons. A 2-sided P , 0.05 was considered statistically significant.
RESULTS
The final analysis included 179 patients (98 men and 81 women), with a mean age of 49 6 12 years (range, 19-73 years). All patients included in the analysis underwent allo-HSCT between July 1996 and July 2011 and were diagnosed with ocular GVHD between August 1997 and August 2011. Patients included in the study were found to have a mean (SD) OSDI score of 50.8 (625.1), Schirmer score of 5.4 mm (65.1), corneal fluorescein staining of 1.7 (61.2), and tear break-up time of 3.3 (62.6). The median time elapsed from transplantation to onset of chronic systemic GVHD was 175 days (6-1477 days) and for chronic ocular GVHD it was 293 days (26-2308 days). In 14 patients (8%), ocular GVHD developed within the first 100 days after transplantation, and, by 1 year, 114 patients (64%) had developed ocular GVHD.
In our cohort, recipients of matched-related transplants had a delayed onset of ocular GVHD (median, 307 days) compared with recipients of matched-unrelated transplants (286 days) and recipients of mismatched-unrelated transplants (231 days). The difference between matched-related and mismatched-unrelated groups was statistically significant (P = 0.015) ( Table 1 ). When pooling groups by HLA match, the group of patients with 5/6 matched transplant (mismatched; n = 29) had a statistically significantly shorter time to onset of ocular GVHD (219 days) than the group of patients with fully matched donors (294 days; n = 150; P = 0.029). In our series, ocular GVHD developed in patients with a previous diagnosis of systemic GVHD in 76% of the cases (136 patients). In this group, individuals with matchedunrelated transplants developed ocular GVHD earlier, after HSCT (296 days), than recipients of matched-related transplants (378 days; P = 0.036). Likewise, the period elapsed between development of systemic and ocular GVHD in individuals with matched-unrelated transplants was shorter (120 days) than in individuals receiving matched-related transplants (250 days; P = 0.004) ( Table 2 ). Systemic GVHD that followed ocular GVHD presented in only 7% of cases (13 patients). Systemic and ocular GVHD occurred simultaneously in 15% of cases (27 patients), and isolated ocular GVHD was present only in 2% of cases (3 patients).
There were no statistically significant differences regarding the time to onset of ocular GVHD among groups defined by the donor-recipient gender-matching status. Other typically known predictive factors for developing GVHD, such as conditioning therapy, medications used for prophylaxis, age of recipient, and systemic organ involvement, did not affect time to onset of ocular GVHD in the population studied (Table 3) .
DISCUSSION
In the population studied, median time to onset of ocular GVHD after bone marrow transplantation was 293 days. There are varying reports on the median time to onset of ocular GVHD after allo-HSCT, one study reported a median of 171 days in 53 patients, whereas another group reported a mean of 13.8 months (414 days) in 48 patients. 14, 15 A possible reason for differences among these reports could be the absence of universally accepted diagnostic criteria for ocular GVHD, because the grading and diagnosis of GVHD continues to retain some subjective aspects. The National Institutes of Health (NIH) Working Committee on Chronic GVHD has published criteria for diagnosis of ocular GVHD based on a positive Schirmer test and other accompanying distinctive features. 1 However, the Schirmer score can be unreliable in patients with dry eye disease and in patients with ocular GVHD. 14, 16 For instance, the NIH system for grading severity of ocular GVHD (based on the dry eye symptoms affecting activities of daily living and number of eye drops required per day) was developed to facilitate the diagnosis of ocular disease by nonophthalmologists (eg, oncologists). However, it is limited by ambiguity and exclusion of objective clinical signs. Other grading systems proposed for ocular GVHD rely exclusively on clinical findings without accounting for patient symptoms. 17, 18 Furthermore, ocular complications as a consequence of total body irradiation, chemotherapy, immunosuppressive therapy, and signs of infections, and meibomian gland dysfunction may confound the diagnosis of ocular GVHD. 15, 19 As per the currently implemented NIH diagnostic criteria for systemic GVHD, ocular GVHD is considered "distinctive" but not "diagnostic," and is insufficient by itself, to establish a diagnosis of GVHD; meaning that a systemic (nonocular) diagnosis of GVHD is required before a definitive diagnosis of ocular GVHD can be made. 1 Three quarters of the population in this study developed ocular GVHD after systemic GVHD; however, 7% of patients were diagnosed with systemic disease up to 2 years after the onset of ocular disease, which is in agreement with the other reports. 7, 14 In this study, we found that 2% of patients developed isolated ocular GVHD in the absence of systemic GVHD; however, in a previous report, the proportion was 12%. 13 Others have reported up to 38% of patients presenting with GVHD-associated dry eye in the absence of systemic GVHD. 20 Consequently, excluding patients with no history of systemic GVHD may lead to overlooking a diagnosis of ocular GVHD, which may manifest simply as acute onset of dry eye disease. In patients with a previous diagnosis of systemic GVHD, attributing ocular symptoms to GVHD is apparent. However, in the absence of systemic GVHD findings (eg, skin, liver, gut disease), signs and symptoms of ocular GVHD may be attributed by clinicians to non-HSCT-related dry eye, with a resultant delay in aggressive management of ocular surface disease. This is a critical point, as our group and others have documented the potential for rapid progression of ocular surface disease in these patients, including unilateral or bilateral corneal perforation, emphasizing the need for aggressive management of "dry eyes" in patients with HSCT. 21, 22 A disparity in major and/or minor HLA antigens is a major risk factor in the development of GVHD. [23] [24] [25] Transplantation from HLA-matched but unrelated donors has been shown to result in a higher incidence of acute systemic GVHD. [26] [27] [28] [29] [30] [31] [32] The findings of the present study show that patients who received mismatched transplantation developed ocular GVHD earlier than those who received fully matched transplants. However, one report found no association of HLA compatibility and dry eye after stem cell transplantation, whereas another study reported a higher prevalence of ocular GVHD in related donor recipients. 33, 34 Inconsistencies in the published literature may be explained by modifications in the type and duration of GVHD prophylaxis, due to continuous advances in transplant medicine, given to mismatched transplant recipients. 35 Additionally, most studies evaluating GVHD are retrospective, spanning various standards of care generations, include heterogeneous patient populations, and do not use consistent diagnostic and staging criteria. Limitations of the present study are largely related to its retrospective design. Patients referred by their primary ophthalmologists or hematologists with a diagnosis of ocular GVHD were included in this study. We would like to emphasize the extraordinary difficulties for the ophthalmologist to follow-up patients with GVHD. These are in many cases extremely ill individuals who are usually followed up in oncology or internal medicine departments, and usually have a variety of systemic manifestations resulting in frequent hospitalization or mortality, which may lead to variable follow-ups to an eye clinic. The study population included only patients who presented ocular GVHD rather than including all patients undergoing bone marrow transplantation; thus, we were unable to derive direct incidence data. The possibility of a recall bias by patients when addressing the exact onset of dry eye symptoms could have also been present. Additionally, the inability to evaluate patients at specific time points after transplantation can result in a later diagnosis of ocular GVHD than if evaluated prospectively at high frequency.
In conclusion, our results suggest onset of chronic ocular GVHD around 1 year post-transplant and support the need for frequent follow-up examinations. After the onset of systemic GVHD, patients receiving transplants from unrelated donors tend to progress to ocular GVHD earlier than those from related donors. In addition, given the high risk for the occurrence of ocular GVHD in post-HSCT patients, it is important to consider that this disease may develop even several years after the transplant. Finally, it is important to emphasize that patients undergoing allo-HSCT may develop severe ocular surface disease as a manifestation of GVHD without a concurrent or preceding history of systemic manifestations of the disease. 
